David Bailey

talk to some of the changes you are seeing in component costs and freight at the moment and maybe also reference any contracting or supply chain changes

One of the most frequent questions we get is the potential return of Philips back into the U.S. device market

where do you think the penetration of the U.S. market is at the moment? And then secondly, in terms of RePAP as an opportunity for growth

interested in your observations around new patients coming into the system and then maybe any feedback you can provide around the physicians prescribing patterns

patients who've initiated GLP one therapy. Just wanted to test the thinking that, you know, patients who lose weight after being on a GLP one might cease their CPAP therapy